-
公开(公告)号:EP2451476A1
公开(公告)日:2012-05-16
申请号:EP10797743.1
申请日:2010-07-06
发明人: ROSSOMANDO, Anthony , MARAGANORE, John , POLLARD, Stuart , KOCISKO, David , MANOHARAN, Muthiah , HINKLE, Greg , BETTENCOURT, Brian , HOGAN, Shannon
CPC分类号: C07K16/2887 , C12N15/1135 , C12N15/1137 , C12N2310/14 , C12Y101/01027
摘要: The invention provides compositions and methods for producing an immunogenic agent from a host cell. In various embodiments, the immunogenic agent is a polypeptide, an antigen, a virus particle, or a vaccine In one aspect, the invention provides for a method for producing an immunogenic agent from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the immunogenic agent from the cell, and isolating the immunogenic agent from the cell.
-
公开(公告)号:EP3234141A1
公开(公告)日:2017-10-25
申请号:EP15871104.4
申请日:2015-12-17
发明人: JADHAV, Vasant , MARAGANORE, John , MAIER, Martin , RAJEEV, Kallanthottathil G. , MANOHARAN, Muthiah , AKINC, Akin , ZLATEV, Ivan
IPC分类号: C12N15/113
CPC分类号: C12N15/111 , C12N15/113 , C12N2310/113 , C12N2310/315 , C12N2310/3183 , C12N2310/319 , C12N2310/3231 , C12N2310/3341 , C12N2310/346 , C12N2310/351 , C12N2310/322 , C12N2310/3533 , C12N2310/321 , C12N2310/3527 , C12N2310/3525 , C12N2310/3521
摘要: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
摘要翻译: 本发明一般涉及调节缀合的siRNA的药理学活性的药剂。
-
公开(公告)号:EP2451940A1
公开(公告)日:2012-05-16
申请号:EP10797723.3
申请日:2010-07-06
发明人: ROSSOMANDO, Anthony , MARAGANORE, John , POLLARD, Stuart , KOCISKO, David , MANOHARAN, Muthiah , BORLAND, Todd , HOGAN, Shannon
CPC分类号: C12N7/00 , C12N15/113 , C12N15/1131 , C12N2310/14
摘要: The present invention relates to molecular biology, molecular genetics, and bioprocessing. The embodiments provide for compositions and methods for producing a biological product, such as an immunogenic agent, in an embryonated egg by introducing into the egg a RNA effector molecule capable of modulating expression of a target gene, wherein the modulation enhances production of the biological product in the egg. These methods provide for RNAi-based approaches to optimize the production of biologics from embryonated eggs, such as the production of viral vaccines including seasonal and pandemic flu vaccines. The invention also relates to molecules, reagents, cells, and kits useful for carrying out the methods, and biological products produced by the methods.
-
-